The SIRT1 targeting resveratrol was proposed to improve outcomes of patients with NAFLD by increasing weight loss and decreasing triglycerides and leptin/adiponectin ratio, but no significant improvement was observed in liver enzymes [101,102,103,104,105]. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.